A retrospective evaluation of the feasibility of intrapatient dose escalation as appropriate methodology for dose-ranging studies for combination cytotoxic regimens

Cancer Chemotherapy and Pharmacology

Volumn 52, Issue 2, 2003, Pages 113-118

  Jordan, Sarah D ^a,c   Poole, Christopher J ^a   Archer, Venice R ^b   Steven, Neil M ^a   Burton, Andrea ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b UNIVERSITY HOSPITALS BIRMINGHAM NHS FOUNDATION TRUST   (United Kingdom)

^c CITY HOSPITAL   (United Kingdom)

Author keywords

Carboplatin; Intrapatient dose escalation; Maximum tolerated dose; Ovarian cancer; Paclitaxel

Indexed keywords

CARBOPLATIN; CYTOTOXIC AGENT; PACLITAXEL;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DOSE CALCULATION; DOSE RESPONSE; DRUG DISTRIBUTION; DRUG INFUSION; FATIGUE; FEMALE; HUMAN; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MAXIMUM TOLERATED DOSE; METHODOLOGY; NEUTROPENIA; NEUTROPHIL; OVARY CANCER; PRIORITY JOURNAL; THROMBOCYTE COUNT; THROMBOCYTOPENIA; TOXICITY;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; DOSE-RESPONSE RELATIONSHIP, DRUG; FEASIBILITY STUDIES; FEMALE; HUMANS; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASM STAGING; OVARIAN NEOPLASMS; PACLITAXEL; RETROSPECTIVE STUDIES;

EID: 0042329726     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-003-0634-8     Document Type: Article

References (34)

1. Bergh J (2000) Where next with stem-cell-supported high-dose therapy for breast cancer? Lancet 355:944-945
2. Bergh J, Wiklund T, Erikstein B, Lidbrink E, Lindman H, Malmstrom P, Kellokumpu-Lehtinen P, Bengtsson NO, Soderlund G, Anker G, Wist E, Ottosson S, Salminen E, Ljungman P, Holte H, Nilsson J, Blomqvist C, Wilking N (2000) Tailored fluorouracil, epirubicin, and cyclophosphamide compared with marrow-supported high-dose chemotherapy as adjuvant treatment for high-risk breast cancer: a randomised trial. Scandinavian Breast Group 9401 study. Lancet 356:1384-1391
3. Bookman MA, McGuire WP 3rd, Kilpatrick D, Keenan E, Hogan WM, Johnson SW, O'Dwyer P, Rowinsky E, Gallion HH, Ozols RF (1996) Carboplatin and paclitaxel in ovarian carcinoma: a phase I study of the Gynecologic Oncology Group. J Clin Oncol 14:1895-1902
4. Calvert AH (1994) Dose optimisation of carboplatin in adults. Anticancer Res 14:2273-2278
5. Calvert AH (1997) A review of the pharmacokinetics and pharmacodynamics of combination carboplatin/paclitaxel. Semin Oncol 24 [Suppl 2]:85-90
6. Calvert A, Newell D, Gumbrell L, O'Reilly S, Burnell M, Boxall F, Siddick Z, Judson I, Gore M, Wiltshaw E (1989) Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol 17:1748-1756
7. Calvert AH, Boddy A, Bailey NP, Siddiqui N, Humphreys A, Hughes A, Robson L, Gumbrell L, Thomas H, Chapman F, Proctor M, Simmons D, Oakey A, Lind M, Sinha D, Newell D (1995) Carboplatin in combination with paclitaxel in advanced ovarian cancer: dose determination and pharmacokinetic and pharmacodynamic interactions. Semin Oncol 22:91-98; discussion 99-100
8. Canal P, Chatelut E, Guichard S (1998) Practical treatment guide for dose individualisation in cancer chemotherapy. Drugs 56:1019-1038
9. Cockcroft DW, Gault MH (1976) Prediction of creatinine clearance from serum creatinine. Nephron 16:31-41
10. Crown J, Lind M, Gould A, Verrill M, Twelves C, Coleman R, Perren T, Belle SV, Wilson C, Lederman J, Barrett-Lee PJ, Heart D, Kennedy I, Simmons P, Mansi JL, Jones A, Cameron D, Poole C, Foster L, Leonard R (2002) High-dose chemotherapy (HDC) with autograft (PBP) support is not superior to cyclophosphamide (CPA), methotrexate and 5-FU (CMF) following doxorubicin (D) induction in patients (pts) with breast cancer (BC) and 4 or more involved axillary lymph nodes (4+LN): the Anglo-Celtic I study. Proc Am Soc Clin Oncol 21:166a
11. Evans WE, Relling MV, Rodman JH, Crom WR, Boyett JM, Pui CH (1998) Conventional compared with individualized chemotherapy for childhood acute lymphoblastic leukemia. N Engl J Med 338:499-505
12. Gordon AN, Hancock KC, Matthews CM, Stringer CA, Boston J, Nemunaitis J (1999) A phase I/II dose escalation study of carboplatin in the treatment of newly diagnosed patients with advanced ovarian cancer receiving paclitaxel. Am J Clin Oncol 22:601-605
13. Gore M, Mainwaring P, A'Hern R, MacFarlane V, Slevin M, Harper P, Osborne R, Mansi J, Blake P, Wiltshaw E, Shepherd J (1998) Randomized trial of dose-intensity with single-agent carboplatin in patients with epithelial ovarian cancer. London Gynaecological Oncology Group. J Clin Oncol 16:2426-2434
14. Harper P (1997) ICON-2 and ICON-3 data in previously untreated ovarian cancer: results to date. Semin Oncol 24 [Suppl 15]:23-25
15. Henderson IC, Berry D, Demetri G, Cirrincione C, Goldstein L, Martino S, Ingle J, Cooper M, Canellos G, Borden E, Fleming G, Holland J, Graziano S, Carpenter J, Muss H, Norton L (1998) Improved disease-free (DFS) and overall survival (OS) from the addition of sequential paclitaxel (T) but not from the escalation of doxorubicin (A) dose level in the adjuvant chemotherapy of patients (pts) with node-positive primary breast cancer (BC). Proc Am Soc Clin Oncol 17:390a
16. Homesley HD, Hall DJ, Martin DA, Lewandowski GS, Vaccarello L, Nahhas WA, Suggs CL, Penley RG (2001) A dose-escalating study of weekly bolus topotecan in previously treated ovarian cancer patients. Gynecol Oncol 83:394-399
17. Jodrell DI, Egorin MJ, Canetta RM, Langenberg P, Goldbloom EP, Burroughs JN, Goodlow JL, Tan S, Wiltshaw E (1992) Relationships between carboplatin exposure and tumor response and toxicity in patients with ovarian cancer. J Clin Oncol 10:520-528
18. Kearns CM, Egorin MJ (1997) Considerations regarding the less-than-expected thrombocytopenia encountered with combination paclitaxel/carboplatin chemotherapy. Semin Oncol 24 [Suppl 2]:91-96
19. Legedza ATR, Ibrahim JG (2000) Longitudinal design for phase I clinical trials using the continual reassessment method. Controlled Clin Trials 21:574-588
20. O'Grady J, Joubert P (eds) (1997) Handbook of phase I/II clinical drug trials. CRC Press, Boca Raton
21. Ozols R, Greer B, Baergen R, Reed E (2002) Gynecologic Oncology Group, Statistical Report Protocol no. 158
22. Pestalozzi B, Schwendener R, Sauter C (1992) Phase I/II study of liposome-complexed mitoxantrone in patients with advanced breast cancer. Ann Oncol 3:445-449
23. Poikonen P, Saarto T, Lundin J, Joensuu H, Blomqvist C (1999) Leucocyte nadir as a marker for chemotherapy efficacy in node-positive breast cancer treated with adjuvant CMF. Br J Cancer 80:1763-1766
24. Poole C, Jordan S, Higgins H, Archer V, Pemberton G (2001) A phase I intra and interpatient dose ranging trial of gemcitabine, carboplatin and paclitaxel (GCP) in combination in previously untreated patients with epithelial ovarian cancer, primary peritoneal malignancy, ovarian carcinosarcoma and fallopian tube carcinoma. Proc Am Soc Clin Oncol 20:848a
25. Rankin E, Mill L, Kaye S, Atkinson R, Cassidy L, Cordiner J, Cruickshank D, Davis J, Duncan I, Fullerton W, Habeshaw T, Kennedy J, Kennedy R, Kitchener H, MacLean A, Paul J, Reed N, Sarker T, Soukoup M, Swapp G, Symonds P (1992) A randomised study comparing standard dose carboplatin with chlorambucil and carboplatin in advanced ovarian cancer. Br J Cancer 65:275-281
26. Rowinsky EK, Flood WA, Sartorius SE, Bowling KM, Ettinger DS (1997) Phase I study of paclitaxel on a 3-hour schedule followed by carboplatin in untreated patients with stage IV non-small cell lung cancer. Invest New Drugs 15:129-138
27. Saarto T, Blomqvist C, Rissanen P, Auvinen A, Elomaa I (1997) Haematological toxicity: a marker of adjuvant chemotherapy efficacy in stage II and III breast cancer. Br J Cancer 75:301-305
28. Seymour L, Eisenhauer E (2001) A review of dose-limiting events in phase I trials: antimetabolites show unpredictable relationships between dose and toxicity. Cancer Chemother Pharmacol 47:2-10
29. Simon R, Freidlin B, Rubinstein L, Arbuck S, Collins J, Christian M (1997) Accelerated titration designs for phase I clinical trials in oncology. J Natl Cancer Inst 89:1138-1147
30. ten Bokkel Huinink W, Veenhof C, Huizing M, Rodenhuis S, Helmerhorst T, Dubbelman R, Dalesio O, Beijnen J, Winograd B (1997) Carboplatin and paclitaxel in patients with advanced ovarian cancer: a dose-finding study. Semin Oncol 24 [Suppl 2]: 31-33
31. van Warmerdam LJ, Huizing MT, Giaccone G, Postmus PE, ten Bokkel Huinink WW, van Zandwijk N, Koolen MG, Helmerhorst TJ, van der Vijgh WJ, Veenhof CH, Beijnen JH (1997) Clinical pharmacology of carboplatin administered in combination with paclitaxel. Semin Oncol 24 [Suppl 2]:97-104
32. Wood WC, Budman DR, Korzun AH, Cooper MR, Younger J, Hart RD, Moore A, Ellerton JA, Norton L, Ferree CR, Ballow A, Frei E, Henderson I (1994) Dose and dose intensity of adjuvant chemotherapy for stage II, node-positive breast carcinoma. N Engl J Med 330:1253-1259
33. Wright JG, Boddy AV, Highley M, Fenwick J, McGill A, Calvert AH (2001) Estimation of glomerular filtration rate in cancer patients. Br J Cancer 84:452-459
34. Zujewski J, Horak ID, Bol CJ, Woestenborghs R, Bowden C, End DW, Piotrovsky VK, Chiao J, Belly RT, Todd A, Kopp WC, Kohler DR, Chow C, Noone M, Hakim FT, Larkin G, Gress RE, Nussenblatt RB, Kremer AB, Cowan KH (2000) Phase I and pharmacokinetic study of farnesyl protein transferase inhibitor R115777 in advanced cancer. J Clin Oncol 18:927-941